UCB (UCB) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategy and foundation

• Patient Value Strategy has guided innovation since 2015, prioritizing differentiated, patient-centered medicines, measurable impact and disease modification.

• More than 9,000 employees; medicines reach over 3.2 million people. R&D investment has remained above the industry average for a decade.

• 25 approvals and launches in key regions over 24 months and 12 consecutive positive Phase III results over four years reflect R&D productivity.

• Patient value also includes access, positive treatment experience and long-term sustainability; net-zero targets validated by the Science Based Targets initiative.

Financial performance and growth

• 2024 projected revenue of ~€6bn, with EBITDA margins at the upper end of 23.0%–24.5%; full-year results expected in February 2025.

• Annual revenue grew 50%, from €3.9bn in 2015 to €6bn projected for 2024; adjusted EBITDA rose 75%, from €0.8bn to €1.4bn.

• Market capitalization tripled from €12bn in 2015 to €37bn projected for 2024.

Growth portfolio

• Five products are in launch phase, supporting a decade-plus growth outlook; the commercial portfolio serves nine patient populations across immunology and neurology.

• BIMZELX targets IL-17A and IL-17F with one antibody; five major approvals came in two months, with strong U.S. commercial coverage and access.

• EVENITY has reached over 725,000 high-risk fracture patients globally; it reduces fragility-fracture rates by 50% and rebuilds bone during a one-year course.

• RYSTIGGO and ZILBRYSQ address different gMG patient needs and preferences, with launches in over 20 countries and real-world use suggesting complementary roles.

• FINTEPLA is approved for Dravet Syndrome and Lennox-Gastaut Syndrome in multiple regions and is available in 17 countries.